Potential value of animal microphysiological systems
Article Sidebar
Main Article Content
Abstract
Microphysiological systems (MPS) are designed to recapitulate aspects of tissue/organ physiology in vivo, thereby providing potential value in safety and efficacy assessments of FDA-regulated products and regulatory decision-making. While there have been significant advances in the development, use, and proposals of qualification criteria for human organ MPS, there remains a gap in the development using animal tissues. Animal MPS may be of value in many areas including the study of zoonotic diseases, assessment of the safety and efficacy of animal therapeutics, and possibly reduction of the use of animals in regulatory submissions for animal therapeutics. In addition, the development of MPS from various animal species enables comparison to animal in vivo data. This comparison, while not always critical for all contexts of use, could help gain confidence in the use and application of human MPS data for regulatory decision-making and for the potential identification of species-specific effects. The use of animal MPS is consistent with the replacement, reduction, and refinement (3Rs) principles of animal use by identifying toxic compounds before conducting in vivo studies and identifying the appropriate species for testing.
Plain language summary
Microphysiological systems (MPS) mimic aspects of organs in humans or animals. These systems may provide information useful for FDA-regulated products. While there have been significant advances in the development of MPS made from human cells, there remains a gap in the development of MPS using animal cells. FDA believes animal MPS may be of value in many areas including the study of diseases transmitted from animals to humans, assessment of the safety and efficacy of animal drugs, and reduction of the use of animals in regulatory submissions. The development of animal MPS enables comparison to data from studies conducted in animals. This comparison provides confidence in the use of human MPS data for regulatory decision-making. The use of animal MPS is consistent with the 3Rs principles of animal use by allowing identification of toxic compounds before conducting animal studies and by helping select the appropriate species for further testing.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).
Avila, A. M., Bebenek, I., Bonzo, J. A. et al. (2020). An FDA/CDER Perspective on Nonclinical Testing Strategies: Classical Toxicology Approaches and New Approach Methodologies (NAMs). Regul Toxicol Pharmacol 114, 104662. doi:10.1016/j.yrtph.2020.104662
Avila, A. M., Bebenek, I., Mendrick, D. L. et al. (2023). Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies. Regul Toxicol Pharmacol 139, 105345. doi:10.1016/j.yrtph.2023.105345
Baran, S. W., Brown, P. C., Baudy, A. R. et al. (2022). Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX 39, 297-314. doi:10.14573/altex.2112203
Berridge, B. R. (2021). Animal study translation: The other reproducibility challenge. ILAR J 62, 1-6. doi:10.1093/ilar/ilac005
Bregman, C. L., Adler R. R., Morton D. G. et al. (2003). Recommended Tissue List for Histopathologic Examination in Repeat-Dose Toxicity and Carcinogenicity Studies: A Proposal of the Society of Toxicologic Pathology (STP). Toxicologic Pathology 31, 252-253. doi:10.1080/01926230390183751
Desta, G. B., Jena, P. K., Hassen, H. M. et al. (2022). Factors associated with zoonosis and reverse zoonosis of mycobacterium tuberculosis and mycobacterium bovis in Ethiopia: A systematic review and meta-analysis. Int. J. Health Sci 6, 1630-1653. doi:10.53730/ijhs.v6nS5.8922
Huh, D., Matthews, B. D., Mammoto, A. et al. (2010). Reconstituting organ-level lung functions on a chip. Science 328, 662-8. doi:10.1126/science.1188302
Irrechukwu, O., Yeager, R., David, R. et al. (2023). Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges. ALTEX 40, 485–518. doi:10.14573/altex.2204071
Jalili-Firoozinezhad, S., Prantil-Baun, R., Jiang, A. et al. (2018). Modeling radiation injury-induced cell death and countermeasure drug responses in a human Gut-on-a-Chip. Cell Death Dis 14, 223. doi:10.1038/s41419-018-0304-8
Jang, K. J., Otieno, M. A., Ronxhi, J. et al. (2019). Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci Transl Med 11, 517. doi:10.1126/scitranslmed.aax5516
Jardi, F., Kelly, C., Teague, C. et al (2023). Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicants. Arch Toxicol 97, 235-254. doi:10.1007/s00204-022-03374-3
Karwelat, D., Kühnlenz, J., Steger-Hartmann, T. et al. (2023). A rodent thyroid-liver chip to capture thyroid toxicity on organ function level. ALTEX 40, 83-102. doi:10.14573/altex.2108262
Kopper, J. J., Iennarella-Servantez, C., Jergens, A. E. et al. (2021). Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health Approach. Front Toxicol 10, 773953. doi:10.3389/ftox.2021.773953
Kühnlenz, J., Karwelat, D., Steger-Hartmann, T. et al. (2023). A microfluidic thyroid-liver platform to assess chemical safety in humans. ALTEX 40, 61-82. doi:10.14573/altex.2108261
Marx, U., Akabane, T., Andersson, T. B. et al. (2020). Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX 37, 365-394. doi:10.14573/altex.2001241
Messenger, A. M., Barnes, A. N., and Gray, G. C. (2014). Reverse zoonotic disease transmission (zooanthroponosis): a systematic review of seldom-documented human biological threats to animals. PloS One 9, e89055. doi:10.1371/journal.pone.0089055
NASEM – National Academies of Science Engineering and Medicine (2021). Microphysiological Systems: Bridging Human and Animal Research: Proceedings of a Workshop—in Brief. National Academies Press (US). doi:10.17226/26124
Pound, P. and Ritskes-Hoitinga, M. (2018). Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med 16, 304. doi:10.1186/s12967-018-1678-1
Sewell, F., Alexander-White C., Brescia S., et al. (2024). New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicol Res (Camb) 13, 1-9. doi:10.1093/toxres/tfae044
Steger-Hartmann, T. and Raschke, M. (2020) Translating in vitro to in vivo and animal to human. Current Opinion in Toxicology 23-24, 6-10. doi:10.1016/j.cotox.2020.02.003
Torisawa, Y. S., Spina, C. S. Mammoto, T. et al. (2014). Bone marrow-on-a-chip replicates hematopoietic niche physiology in vitro. Nat Methods 11, 663-669. doi:10.1038/nmeth.2938
Weinhart, M., Hocke, A., Hippenstiel, S. et al. (2019). 3D organ models-Revolution in pharmacological research? Pharmacol Res 139, 446-451. doi:10.1016/j.phrs.2018.11.002
Willy, M. E., Woodward, R. A., Thornton, V. B. et al. (1999). Management of a measles outbreak among Old World nonhuman primates. Lab Anim Sci 49, 42-48. doi:10.1016/j.phrs.2018.11.002
Zhou, J., Cun, L., Ziu, X., et al. (2020). Infection of bat and human intestinal organoids by SARS-CoV-2. Nature Medicine 26, 1077-1083. doi:10.1038/s41591-020-0912-6